Clinical Trial

Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label, single-arm, dose-escalation study in up to 20 participants with relapsed/refractory Neuromyelitis Optica Spectrum Disorders (NMOSD). The aim is to evaluate the safety and efficacy of the treatment with BAFFR CART.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-08-16.
Trial Details
NCT Number NCT06561009
Lead Sponsor Tianjin Medical University General Hospital
Conditions Neuromyelitis Optica Spectrum Disorder
Enrollment 20 participants
Start Date 2025-12-01
Primary Completion 2027-10-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2025-05-30